《Science》癌症特刊：PARP抑制剂深度盘点-上海交大医学院图书馆
随着临床前研究发现PARP抑制与BRCA基因突变之间的合成致死关系，olaparib (KuDOS/阿斯利康) 被推进临床1期试验，治疗携带BRCA1或BRCA2种系基因突变的乳腺癌患者。
PARP Inhibition in BRCA-Mutant Breast Cancer - PMC - PubMed …
The Poly(ADP-ribose) polymerase (PARP) enzymes play a key role in BER and PARP inhibitors (PARPi) are effective in causing cell death in BRCA-mutant cells while sparing normal cells-a …
PARP inhibitors: review of mechanisms of action and BRCA1/2 …
Poly (ADP-ribose) polymerases have shown true promise in early clinical studies due to reported activity in BRCA-associated cancers. PARP inhibitors may represent a potentially important …
PARPi, BRCA, and gaps: controversies and future research - Cell …
2024年7月13日 · Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are approved drugs used in neoadjuvant, adjuvant, or maintenance therapies for the treatment of breast, ovarian, …
Combination strategies with PARP inhibitors in BRCA-mutated …
2024年11月21日 · Poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as a promising targeted treatment for BRCA-mutated TNBC, exploiting vulnerabilities in the …
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer ...
2016年10月13日 · Poly (ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA -mutated …
Olaparib as treatment for platinum‐sensitive relapsed ovarian …
1 天前 · Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis …
Frontiers | Targeting the BRCA1/2 deficient cancer with PARP …
2023年3月21日 · Currently, the Food and Drug Administration (FDA) has approved four PARP inhibitors (PARPi) to treat cancers with BRCA1/2 mutations. In this review, we will first …
PARP inhibition with rucaparib alone followed by combination …
2024年7月6日 · Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in …
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA …
Poly (ADP-ribose)polymerase inhibitors (PARPis) have shown promising activity in patients with BRCA1/2 mutation-associated (BRCA1/2 MUT+) ovarian and breast cancers.